Last reviewed · How we verify

Patidegib Topical Gel — Competitive Intelligence Brief

Patidegib Topical Gel (Patidegib Topical Gel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Smoothened (SMO) inhibitor. Area: Oncology.

phase 3 Smoothened (SMO) inhibitor Smoothened (SMO) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Patidegib Topical Gel (Patidegib Topical Gel) — Sol-Gel Technologies, Ltd.. Patidegib is a smoothened (SMO) inhibitor that blocks hedgehog signaling pathway activation, reducing abnormal cell proliferation in skin tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Patidegib Topical Gel TARGET Patidegib Topical Gel Sol-Gel Technologies, Ltd. phase 3 Smoothened (SMO) inhibitor Smoothened (SMO)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Smoothened (SMO) inhibitor class)

  1. Sol-Gel Technologies, Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Patidegib Topical Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/patidegib-topical-gel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: